Etude de marché des syndic de copropriété du departement Indre(36) en France

Download in Excel, CSV or JSON

Etude de marché des syndic de copropriété du departement Indre(36) en France. Cette liste vous donne les détails administratifs de chaque société, ainsi que le chiffre d'affaire, le résultat, le nombre d'employés (effectif), la profitabilité et la croissance pour les trois dernières années. Cette liste a été constituée en utilisant les fichiers de la base SIREN fournie par l'INSEE ainsi que les fichiers des greffes des tribunaux de commerce (Infogreffe).
Code NAF de syndic de copropriété : 68.32A : Administration d'immeubles et autres biens immobiliers.
Nombre de syndic de copropriété: Le departement Indre(36) a 92 syndic de copropriété.
Le nombre d'habitants du departement Indre est de 217139.
Densité de syndic de copropriété: en Indre, il y a 2360.21 habitants par syndic de copropriété.
Le pouvoir d'achat quotidien potentiel moyen de la zone de chalandise par syndic de copropriété en Indre est de: 5835.85 €.
Les chiffres d'affaires, profits et nombre d'employés peuvent être calculés sur un petit nombre d'échantillons, car une faible proportion d'entreprises publient leurs résultats. Ce nombre limité d'échantillons peut induire des données ayant un écart significatif avec la réalité.
Le fichier disponible 'Densité rentabilité syndic de copropriété France par département' est disponible sur Basedig et fourni des analyses de rentabilité potentielles par activité pour ce type d'activité.
Basedig fourni egalement des analyses sur la croissance du nombre de syndic de copropriété ainsi que des alertes mensuelles fournissant des listes précises de création de syndic de copropriété par département dans toute la France. N'hésitez pas à nous contacter pour plus d'informations.
Les fichiers d'entreprises disponibles sur Basedig peuvent être utilisés pour réaliser des études de marché, pour la prospection, le démarchage, la réalisation de business plan, le planning stratégique de réseaux de vente ou de franchise. D'autres listes et fichiers pour d'autres types d'activités et d'unités légales de la base SIREN et d'autres départements sont disponibles sur Basedig. Des analyses du potentiel économique, avec des données précises de chiffre d'affaire, de croissance, de nombre d'employés et de profitabilité par département peuvent également être téléchargées.
Cet annuaire est disponible en téléchargement. Il est possible de le télécharger sous forme de fichier Excel, fichier CSV ou JSON.

Data Source : BASE SIREN INSEE
Number of Data columns : 20 Number of Data rows : 92
Categories : BASESIREN, LIST, UNITS, BY, DEPARTMENT, INFOGREFFE, REVENUES, STATISTICS

Dataset

Data row number Siret NafCode Street Address Zipcode City Country Company Name Siren Last Reporting Year Number Employees Min Revenues 2017 Net Earnings 2017 Net Earnings 2018 Revenues 2016 Number Employees Max Net Earnings 2016 Revenues 2018 Head Office Creation Date Registration Start Date

Download the dataset to see the full list of 92 entries

Data Columns

Name Description Data Type
Siret text
NafCode text
Street Address text
Zipcode text
City text
Country text
Company Name text
Siren text
Last Reporting Year bigint
Number Employees Min bigint
Revenues 2017 bigint
Net Earnings 2017 bigint
Net Earnings 2018 bigint
Revenues 2016 bigint
Number Employees Max bigint
Net Earnings 2016 bigint
Revenues 2018 bigint
Head Office text
Creation Date text
Registration Start Date text

€15.00 incl. VAT

Other datasets published on Basedig

Liste de sondages sur l'élection présidentielle française de 2017 par région - Sondages du deuxième tour - Mélenchon - Fillon

From WIKIPEDIA

Structured data parsed from Wikipedia. Mélenchon Fillon Auvergne Rhône Alpes Auvergne Rhône Alpes 56 % Bourgogne Franche Comté Bourgogne Franche Comté

fillon, melenchon, sondages, election, liste

- 1 January

From WIKIPEDIA

Structured data parsed from Wikipedia. 1 January

january, 1, wikipedia, parsed, structured

Women's Health Initiative - Study components and primary findings - Hormone therapy (HT) intervention

From WIKIPEDIA

Structured data parsed from Wikipedia. Hormone therapy (HT) intervention The design of the hormone therapy trial (HT) was approached with the hypothesis that estrogen therapy would result in a decrease in coronary heart disease and osteoporosis related fractures. As such, the primary outcome of interest was coronary heart disease, as this is a major cause of morbidity and mortality among women, particularly those over age 65, and because, at the time, no clinical trial had been undertaken to prove the cardioprotective effects of HT. Due to the concern over the relationship between HT and elevated breast cancer risk, breast cancer was selected as the primary adverse outcome. Additional outcomes monitored included stroke, pulmonary embolism (PE), endometrial cancer, colorectal cancer, hip fracture, and death due to other causes. Two regimens were selected, in addition to a placebo group. Women assigned to the intervention group who had previously undergone a hysterectomy were treated with unopposed estrogen, specifically conjugated estrogens (Premarin, manufactured by Wyeth), at a dosage of 0.625 mg/day ('E alone,' n = 5310; placebo, n = 5429). Women with an intact uterus were treated by a combined estrogen plus progestin regimen ('E+P,' n = 8506; placebo, n = 8102), specifically the aforementioned estrogen regimen with the addition of 2.5 mg/day of medroxyprogesterone acetate (MPA; Prempro, also manufactured by Wyeth). The addition of progestin has been linked to a marked reduction in the risk for the development of endometrial cancer in women receiving estrogen treatment who have not undergone a hysterectomy. In addition to the global exclusion criteria, women were ineligible for the HT component if safety was a concern. Such concerns included a breast cancer diagnosis at any time in the past, other cancers (excluding non melanoma skin cancer) diagnosed within the previous 10 years, or low hematocrit or platelet counts. HT component findings and ensuing events HT component findings and ensuing events The HT component had originally been designed to include a follow up period of nine years. However, interim monitoring of the combined estrogen/progestin treatment group indicated an increased risk of breast cancer, coronary heart disease, stroke, and pulmonary embolism, which outweighed the evidence indicating a benefit in preventing colorectal cancer and fractures. As a consequence, the HT study pills were stopped in July 2002, with an average follow up period of 5.2 years. The unopposed estrogen trial was halted in February 2004, after an average follow up period of 6.8 years, on the basis that unopposed estrogen did not appear to affect the risk of heart disease, the primary outcome, which was in contrast to the findings of previous observational studies. On the other hand, there were indications for an increased risk of stroke. Unopposed estrogen did reduce the risk for osteoporotic fractures and, unlike the estrogen/progestin treatment, showed a decrease in breast cancer risk. As a consequence of the findings, which indicated that the incurred risks of HT outweigh the identified benefits, the study authors recommended that HT not be prescribed for the purpose of chronic disease prevention in postmenopausal women. The hypothesized and observed risks of specific clinical outcomes are summarized in the following table. Of particular interest are the contrasts between several of the hypothesized risks and the observed attributable risks, which are instructive in demonstrating the distinct differences between the HT trial findings and those of previous observational studies. Hazard Ratios (HR) and 95% confidence intervals (CIs) for various clinical outcomes in the E+P and E alone trials Hazard Ratios (HR) and 95% confidence intervals (CIs) for various clinical outcomes in the E+P and E alone trials

and, ht, women, findings, therapy